Market Research Life Sciences Market Research Biotechnology Market Research Stem Cell Market Research

Cell and Gene Therapy Manufacturing Market (Therapy Type: Cell Therapy and Gene Therapy; Product Type: Consumables, Equipment, and Software) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 284 Pages Transparency Market Research Pvt. Ltd. August, 2023 TNPR18249866
Best Price Guarantee
Price from $5,795
Length 284 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date August, 2023
SKU TNPR18249866

Cell and Gene Therapy Manufacturing Market (Therapy Type: Cell Therapy and Gene Therapy; Product Type: Consumables, Equipment, and Software) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Cell and Gene Therapy Manufacturing Market – Scope of Report

TMR’s report on the global cell and gene therapy manufacturing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell and gene therapy manufacturing market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell and gene therapy manufacturing market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cell and gene therapy manufacturing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell and gene therapy manufacturing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell and gene therapy manufacturing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell and gene therapy manufacturing market.

The report delves into the competitive landscape of the global cell and gene therapy manufacturing market. Key players operating in the global cell and gene therapy manufacturing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell and gene therapy manufacturing market profiled in this report.

Key Questions Answered in Global Cell and Gene Therapy Manufacturing Market Report
  • What is the sales/revenue generated by cell and gene therapy manufacturing across all regions during the forecast period?
  • What are the opportunities in the global cell and gene therapy manufacturing market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Cell and Gene Therapy Manufacturing Market – Research Objectives and Research Approach

The comprehensive report on the global cell and gene therapy manufacturing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell and gene therapy manufacturing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell and gene therapy manufacturing market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Cell and Gene Therapy Manufacturing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancements
5.2. Reimbursement Scenario by Region/Globally
5.3. Regulatory Scenario by Region/globally
5.4. Disease Prevalence & Incidence Rate Globally With Key Countries
5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapy Type, 2017-2031
6.3.1. Cell Therapy
6.3.1.1. Allogeneic
6.3.1.1.1. Mesenchymal Stem Cells
6.3.1.1.2. T-cells
6.3.1.1.3. Induced Pluripotent Stem Cells
6.3.1.1.4. Natural Killer Cells
6.3.1.1.5. Hematopoietic Stem Cells
6.3.1.1.6. Others
6.3.1.2. Autologous
6.3.1.2.1. T-cells
6.3.1.2.2. Hematopoietic Stem Cells
6.3.1.2.3. Mesenchymal Stem Cells
6.3.1.2.4. Natural Killer Cells
6.3.1.2.5. Others
6.3.2. Gene Therapy
6.3.2.1. Viral Vector
6.3.2.1.1. Lentiviral Vector
6.3.2.1.2. Adeno-associated Virus Vectors
6.3.2.1.3. Other Viral Vectors
6.3.2.2. Non-viral Vector
6.3.2.2.1. Electroporation
6.3.2.2.2. Other Non-viral Vectors
6.4. Market Attractiveness Analysis, by Therapy Type
7. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Product Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Product Type, 2017-2031
7.3.1. Consumables
7.3.2. Equipment
7.3.2.1. Cell Processing Equipment
7.3.2.2. Single-use Equipment
7.3.2.3. Other Equipment
7.3.3. Software & Systems
7.4. Market Attractiveness Analysis, by Product Type
8. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Technology
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Technology, 2017-2031
8.3.1. Cell Culture & Expansion
8.3.2. Viral Vector Production
8.3.3. Cell Sorting & Purification
8.3.4. Gene Editing
8.3.5. Others
8.4. Market Attractiveness Analysis, by Technology
9. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Indication
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Indication, 2017-2031
9.3.1. Oncology Disease
9.3.2. Cardiovascular Disease
9.3.3. Orthopedic Disease
9.3.4. Infectious Disease
9.3.5. Others
9.4. Market Attractiveness Analysis, by Indication
10. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2017-2031
10.3.1. Pharmaceutical & Biotechnology Companies
10.3.2. Contract Manufacturing Organizations (CMOs)
10.4. Market Attractiveness Analysis, by End-user
11. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017-2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Cell and Gene Therapy Manufacturing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy Type, 2017-2031
12.2.1. Cell Therapy
12.2.1.1. Allogeneic
12.2.1.1.1. Mesenchymal Stem Cells
12.2.1.1.2. T-cells
12.2.1.1.3. Induced Pluripotent Stem Cells
12.2.1.1.4. Natural Killer Cells
12.2.1.1.5. Hematopoietic Stem Cells
12.2.1.1.6. Others
12.2.1.2. Autologous
12.2.1.2.1. T-cells
12.2.1.2.2. Hematopoietic Stem Cells
12.2.1.2.3. Mesenchymal Stem Cells
12.2.1.2.4. Natural Killer Cells
12.2.1.2.5. Others
12.2.2. Gene Therapy
12.2.2.1. Viral Vector
12.2.2.1.1. Lentiviral Vector
12.2.2.1.2. Adeno-associated Virus Vectors
12.2.2.1.3. Other Viral Vectors
12.2.2.2. Non-viral Vector
12.2.2.2.1. Electroporation
12.2.2.2.2. Other Non-viral Vectors
12.3. Market Value Forecast, by Product Type, 2017-2031
12.3.1. Consumables
12.3.2. Equipment
12.3.2.1. Cell Processing Equipment
12.3.2.2. Single-use Equipment
12.3.2.3. Other Equipment
12.3.3. Software & Systems
12.4. Market Value Forecast, by Technology, 2017-2031
12.4.1. Cell Culture & Expansion
12.4.2. Viral Vector Production
12.4.3. Cell Sorting & Purification
12.4.4. Gene Editing
12.4.5. Others
12.5. Market Value Forecast, by Indication, 2017-2031
12.5.1. Oncology Disease
12.5.2. Cardiovascular Disease
12.5.3. Orthopedic Disease
12.5.4. Infectious Disease
12.5.5. Others
12.6. Market Value Forecast, by End-user, 2017-2031
12.6.1. Pharmaceutical & Biotechnology Companies
12.6.2. Contract Manufacturing Organizations (CMOs)
12.7. Market Value Forecast, by Country, 2017-2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Therapy Type
12.8.2. By Product Type
12.8.3. By Technology
12.8.4. By Indication
12.8.5. By End-user
12.8.6. By Country
13. Europe Cell and Gene Therapy Manufacturing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy Type, 2017-2031
13.2.1. Cell Therapy
13.2.1.1. Allogeneic
13.2.1.1.1. Mesenchymal Stem Cells
13.2.1.1.2. T-cells
13.2.1.1.3. Induced Pluripotent Stem Cells
13.2.1.1.4. Natural Killer Cells
13.2.1.1.5. Hematopoietic Stem Cells
13.2.1.1.6. Others
13.2.1.2. Autologous
13.2.1.2.1. T-cells
13.2.1.2.2. Hematopoietic Stem Cells
13.2.1.2.3. Mesenchymal Stem Cells
13.2.1.2.4. Natural Killer Cells
13.2.1.2.5. Others
13.2.2. Gene Therapy
13.2.2.1. Viral Vector
13.2.2.1.1. Lentiviral Vector
13.2.2.1.2. Adeno-associated Virus Vectors
13.2.2.1.3. Other Viral Vectors
13.2.2.2. Non-viral Vector
13.2.2.2.1. Electroporation
13.2.2.2.2. Other Non-viral Vectors
13.3. Market Value Forecast, by Product Type, 2017-2031
13.3.1. Consumables
13.3.2. Equipment
13.3.2.1. Cell Processing Equipment
13.3.2.2. Single-use Equipment
13.3.2.3. Other Equipment
13.3.3. Software & Systems
13.4. Market Value Forecast, by Technology, 2017-2031
13.4.1. Cell Culture & Expansion
13.4.2. Viral Vector Production
13.4.3. Cell Sorting & Purification
13.4.4. Gene Editing
13.4.5. Others
13.5. Market Value Forecast, by Indication, 2017-2031
13.5.1. Oncology Disease
13.5.2. Cardiovascular Disease
13.5.3. Orthopedic Disease
13.5.4. Infectious Disease
13.5.5. Others
13.6. Market Value Forecast, by End-user, 2017-2031
13.6.1. Pharmaceutical & Biotechnology Companies
13.6.2. Contract Manufacturing Organizations (CMOs)
13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Therapy Type
13.8.2. By Product Type
13.8.3. By Technology
13.8.4. By Indication
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Cell and Gene Therapy Manufacturing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapy Type, 2017-2031
14.2.1. Cell Therapy
14.2.1.1. Allogeneic
14.2.1.1.1. Mesenchymal Stem Cells
14.2.1.1.2. T-cells
14.2.1.1.3. Induced Pluripotent Stem Cells
14.2.1.1.4. Natural Killer Cells
14.2.1.1.5. Hematopoietic Stem Cells
14.2.1.1.6. Others
14.2.1.2. Autologous
14.2.1.2.1. T-cells
14.2.1.2.2. Hematopoietic Stem Cells
14.2.1.2.3. Mesenchymal Stem Cells
14.2.1.2.4. Natural Killer Cells
14.2.1.2.5. Others
14.2.2. Gene Therapy
14.2.2.1. Viral Vector
14.2.2.1.1. Lentiviral Vector
14.2.2.1.2. Adeno-associated Virus Vectors
14.2.2.1.3. Other Viral Vectors
14.2.2.2. Non-viral Vector
14.2.2.2.1. Electroporation
14.2.2.2.2. Other Non-viral Vectors
14.3. Market Value Forecast, by Product Type, 2017-2031
14.3.1. Consumables
14.3.2. Equipment
14.3.2.1. Cell Processing Equipment
14.3.2.2. Single-use Equipment
14.3.2.3. Other Equipment
14.3.3. Software & Systems
14.4. Market Value Forecast, by Technology, 2017-2031
14.4.1. Cell Culture & Expansion
14.4.2. Viral Vector Production
14.4.3. Cell Sorting & Purification
14.4.4. Gene Editing
14.4.5. Others
14.5. Market Value Forecast, by Indication, 2017-2031
14.5.1. Oncology Disease
14.5.2. Cardiovascular Disease
14.5.3. Orthopedic Disease
14.5.4. Infectious Disease
14.5.5. Others
14.6. Market Value Forecast, by End-user, 2017-2031
14.6.1. Pharmaceutical & Biotechnology Companies
14.6.2. Contract Manufacturing Organizations (CMOs)
14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Therapy Type
14.8.2. By Product Type
14.8.3. By Technology
14.8.4. By Indication
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Cell and Gene Therapy Manufacturing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapy Type, 2017-2031
15.2.1. Cell Therapy
15.2.1.1. Allogeneic
15.2.1.1.1. Mesenchymal Stem Cells
15.2.1.1.2. T-cells
15.2.1.1.3. Induced Pluripotent Stem Cells
15.2.1.1.4. Natural Killer Cells
15.2.1.1.5. Hematopoietic Stem Cells
15.2.1.1.6. Others
15.2.1.2. Autologous
15.2.1.2.1. T-cells
15.2.1.2.2. Hematopoietic Stem Cells
15.2.1.2.3. Mesenchymal Stem Cells
15.2.1.2.4. Natural Killer Cells
15.2.1.2.5. Others
15.2.2. Gene Therapy
15.2.2.1. Viral Vector
15.2.2.1.1. Lentiviral Vector
15.2.2.1.2. Adeno-associated Virus Vectors
15.2.2.1.3. Other Viral Vectors
15.2.2.2. Non-viral Vector
15.2.2.2.1. Electroporation
15.2.2.2.2. Other Non-viral Vectors
15.3. Market Value Forecast, by Product Type, 2017-2031
15.3.1. Consumables
15.3.2. Equipment
15.3.2.1. Cell Processing Equipment
15.3.2.2. Single-use Equipment
15.3.2.3. Other Equipment
15.3.3. Software & Systems
15.4. Market Value Forecast, by Technology, 2017-2031
15.4.1. Cell Culture & Expansion
15.4.2. Viral Vector Production
15.4.3. Cell Sorting & Purification
15.4.4. Gene Editing
15.4.5. Others
15.5. Market Value Forecast, by Indication, 2017-2031
15.5.1. Oncology Disease
15.5.2. Cardiovascular Disease
15.5.3. Orthopedic Disease
15.5.4. Infectious Disease
15.5.5. Others
15.6. Market Value Forecast, by End-user, 2017-2031
15.6.1. Pharmaceutical & Biotechnology Companies
15.6.2. Contract Manufacturing Organizations (CMOs)
15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Therapy Type
15.8.2. By Product Type
15.8.3. By Technology
15.8.4. By Indication
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Cell and Gene Therapy Manufacturing Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Therapy Type, 2017-2031
16.2.1. Cell Therapy
16.2.1.1. Allogeneic
16.2.1.1.1. Mesenchymal Stem Cells
16.2.1.1.2. T-cells
16.2.1.1.3. Induced Pluripotent Stem Cells
16.2.1.1.4. Natural Killer Cells
16.2.1.1.5. Hematopoietic Stem Cells
16.2.1.1.6. Others
16.2.1.2. Autologous
16.2.1.2.1. T-cells
16.2.1.2.2. Hematopoietic Stem Cells
16.2.1.2.3. Mesenchymal Stem Cells
16.2.1.2.4. Natural Killer Cells
16.2.1.2.5. Others
16.2.2. Gene Therapy
16.2.2.1. Viral Vector
16.2.2.1.1. Lentiviral Vector
16.2.2.1.2. Adeno-associated Virus Vectors
16.2.2.1.3. Other Viral Vectors
16.2.2.2. Non-viral Vector
16.2.2.2.1. Electroporation
16.2.2.2.2. Other Non-viral Vectors
16.3. Market Value Forecast, by Product Type, 2017-2031
16.3.1. Consumables
16.3.2. Equipment
16.3.2.1. Cell Processing Equipment
16.3.2.2. Single-use Equipment
16.3.2.3. Other Equipment
16.3.3. Software & Systems
16.4. Market Value Forecast, by Technology, 2017-2031
16.4.1. Cell Culture & Expansion
16.4.2. Viral Vector Production
16.4.3. Cell Sorting & Purification
16.4.4. Gene Editing
16.4.5. Others
16.5. Market Value Forecast, by Indication, 2017-2031
16.5.1. Oncology Disease
16.5.2. Cardiovascular Disease
16.5.3. Orthopedic Disease
16.5.4. Infectious Disease
16.5.5. Others
16.6. Market Value Forecast, by End-user, 2017-2031
16.6.1. Pharmaceutical & Biotechnology Companies
16.6.2. Contract Manufacturing Organizations (CMOs)
16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Therapy Type
16.8.2. By Product Type
16.8.3. By Technology
16.8.4. By Indication
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. Becton, Dickinson and Company
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Bio-Rad Laboratories, Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Bio-Techne Corporation
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Danaher Corporation
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. General Electric Company (GE Healthcare)
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Getinge AB
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Lonza Group Ltd.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Merck KGaA
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Sartorius AG (Sartorius Stedim Biotech S.A.)
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Thermo Fisher Scientific Inc.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
17.3.11. MaxCyte
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Product Portfolio
17.3.11.3. Financial Overview
17.3.11.4. SWOT Analysis
17.3.11.5. Strategic Overview
17.3.12. Fresenius Medical Care AG & Co. KGaA
17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.12.2. Product Portfolio
17.3.12.3. Financial Overview
17.3.12.4. SWOT Analysis
17.3.12.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings